<?xml version="1.0" encoding="ISO-8859-1" ?>
<rss version="2.0" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:atom="http://www.w3.org/2005/Atom">
	<channel>
		<title>PR.com Press Releases: curasan AG News</title>
		<link>http://www.PR.com/</link>
		<description>Latest news releases from PR.com for curasan AG.</description>
		<lastBuildDate>Sat, 20 Mar 2010 02:53:03 -0400</lastBuildDate>
		<copyright>&#169; 2010 PR Worldwide, Inc.</copyright>
		<ttl>60</ttl>
		<language>en-us</language>
		<image>
			<url>http://www.PR.com/images/logo_white.jpg</url>
			<title>PR.com Press Releases: curasan AG News</title>
			<link>http://www.PR.com/</link>
			<width>68</width>
			<height>69</height>
			<description>PR.com provides Free Press Release Distribution, &amp; is a unique Directory of Businesses, Products, Services, &amp; Jobs - in all industries.  Find Full Company Profiles.</description>
		</image>
		<atom:link href="http://www.pr.com/rss/press-releases-2/103108.xml" rel="self" type="application/rss+xml" />
		<item>
			<guid isPermaLink="true">http://www.pr.com/press-release/220228</guid>
			<title>curasan AG Launches Bone Substitute Osbone&#174; &#8211; The Synthetic Alternative Without Biological History</title>
			<pubDate>Thu, 18 Mar 2010 03:00:00 -0400</pubDate>
			<description>In Germany alone, every year about 800,000 tooth implants are placed. In the case of almost every second patient bone augmentation is necessary, because the jawbone atrophy is already too advanced. The development of bone substitute materials has advanced considerably over the last few years, particularly in the area of scaffold substances. There is a broad spectrum ranging from autologous, fully synthetic to xenogenic [PR.com]</description>
			<link>http://www.pr.com/press-release/220228</link>
			<dc:creator>curasan AG</dc:creator>
		</item>
		<item>
			<guid isPermaLink="true">http://www.pr.com/press-release/213969</guid>
			<title>curasan AG: New US Subsidiary for Orthopaedics</title>
			<pubDate>Sat, 20 Feb 2010 03:00:00 -0500</pubDate>
			<description>curasan AG, listed in the General Standard of the Deutsche B&#246;rse AG, is commencing the sale, through a subsidiary, of its synthetic bone regeneration material Cerasorb&#174; M Ortho in the United States. [PR.com]</description>
			<link>http://www.pr.com/press-release/213969</link>
			<dc:creator>curasan AG</dc:creator>
		</item>
		<item>
			<guid isPermaLink="true">http://www.pr.com/press-release/199464</guid>
			<title>Curavisc&#174;: Successful Study Regarding the Treatment of Chronic Facet Syndrome</title>
			<pubDate>Wed, 16 Dec 2009 03:00:00 -0500</pubDate>
			<description>A new study was presented at the 4th Annual Congress of the German Spine Society in Munich &#8211; it demonstrated the long-term effect of Curavisc&#174; in the treatment of chronic facet syndrome [PR.com]</description>
			<link>http://www.pr.com/press-release/199464</link>
			<dc:creator>curasan AG</dc:creator>
		</item>
		<item>
			<guid isPermaLink="true">http://www.pr.com/press-release/198857</guid>
			<title>curasan AG Receives License for Osbone&#174;</title>
			<pubDate>Sat, 12 Dec 2009 03:00:00 -0500</pubDate>
			<description>curasan AG has received CE certification and, therefore, marketing authorization throughout Europe of the synthetic bone replacement material Osbone&#174;. [PR.com]</description>
			<link>http://www.pr.com/press-release/198857</link>
			<dc:creator>curasan AG</dc:creator>
		</item>
		<item>
			<guid isPermaLink="true">http://www.pr.com/press-release/193812</guid>
			<title>curasan AG Signs a Research Agreement with Ben-Gurion University</title>
			<pubDate>Thu, 19 Nov 2009 03:00:00 -0500</pubDate>
			<description>curasan AG, which is listed on the General Standard of the German Stock Exchange, has signed a research and development agreement with the Ben-Gurion University of the Negev (BGU), Israel. [PR.com]</description>
			<link>http://www.pr.com/press-release/193812</link>
			<dc:creator>curasan AG</dc:creator>
		</item>
		<item>
			<guid isPermaLink="true">http://www.pr.com/press-release/186482</guid>
			<title>curasan AG Received Licence for ATR&#174;</title>
			<pubDate>Sun, 18 Oct 2009 03:00:00 -0400</pubDate>
			<description>curasan AG has received CE certification and, therefore, marketing authorization for the ATR&#174; (Advanced Tissue Regeneration) product. [PR.com]</description>
			<link>http://www.pr.com/press-release/186482</link>
			<dc:creator>curasan AG</dc:creator>
		</item>
		<item>
			<guid isPermaLink="true">http://www.pr.com/press-release/185200</guid>
			<title>curasan AG to Invest Approximately 1 Million Euros in Future Growth &#8211; Product Pipeline Well Filled</title>
			<pubDate>Wed, 14 Oct 2009 03:00:00 -0400</pubDate>
			<description>curasan AG is to invest in its future growth by implementing a technological investment programme amounting to approximately 1 million euros, despite the current crisis in the financial markets [PR.com]</description>
			<link>http://www.pr.com/press-release/185200</link>
			<dc:creator>curasan AG</dc:creator>
		</item>
		<item>
			<guid isPermaLink="true">http://www.pr.com/press-release/178638</guid>
			<title>curasan AG Receives &#8364;1.48 Million Research Grant</title>
			<pubDate>Wed, 16 Sep 2009 03:00:00 -0400</pubDate>
			<description>curasan AG, listed on the General Standard of Deutsche B&#246;rse AG as ISIN: DE 000 549 453 8, has just received a grant of &#8364;1.48 million from the German Federal Ministry of Education and Research (Bundesministerium f&#252;r Bildung und Forschung, BMBF) for a bone regeneration research project scheduled to last three years. The funds are earmarked for a joint project with Ben Gurion University (BGU) of the Negev, [PR.com]</description>
			<link>http://www.pr.com/press-release/178638</link>
			<dc:creator>curasan AG</dc:creator>
		</item>
	</channel>
</rss>